Clinical Catalysts Drive Biotech Movers: Opus Genetics, Quantum & More

Opus Genetics (NASDAQ:IRD) received FDA clearance for its gene therapy OPGx-RDH12, targeting RDH12-associated Leber congenital amaurosis. The company plans to start a Phase 1/2 trial this quarter. The therapy aims to restore retinal function in a rare inherited disease affecting 30,900 people globally. Opus Genetics collaborates with the Global RDH12 Alliance, which committed up to $1.6 million for development.

Quantum BioPharma (QNTM) was featured in a Men's Fitness article discussing clinical trial results for Unbuzzd, an alcohol recovery formulation. The study, sponsored by the company, showed lower blood alcohol levels, improved alertness, and reduced headache severity in some participants. However, the article noted limitations, including small sample size and mixed results, and called for larger, independent trials. Quantum developed the formulation and licensed it to Unbuzzd Wellness.

Quantum BioPharma's Unbuzzd study, cited in Men’s Fitness, showed lower estimated BAC and improved alertness in 26 adults, though results were mixed and sample size was small. The company-sponsored, placebo-controlled trial requires larger trials for validation, according to the report.

Opus Genetics (IRD) received FDA approval to expand Ryzumvi's use to adults with presbyopia, a milestone that triggers a payment from partner Viatris (VTRS). IRD's P/S ratio is 29.84, far above its historical median, reflecting high growth expectations despite its unprofitability. The company's GF Score is 21, indicating financial and operational challenges, and insiders have sold $19.3M in shares over the past year.

Opus Genetics (IRD) received FDA approval for its phentolamine ophthalmic solution, triggering a licensing agreement payment. The company trades at a high P/S ratio of 30.33, reflecting growth expectations despite financial challenges. Insider activity shows significant selling. The FDA approval follows successful clinical trials for presbyopia treatment.

Opus Genetics (IRD) received FDA approval for RYZUMVI, a drug to treat presbyopia in adults. The approval expands the drug's use beyond its initial indication. The company has a licensing agreement with Viatris (VTRS), which holds U.S. commercialization rights. The FDA approval triggers a milestone payment to Opus Genetics, though the amount was not disclosed.